Related Experiment Video
Updated: Aug 11, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
A species comparison of chloral hydrate metabolism in blood and liver
J C Lipscomb1, D A Mahle, W T Brashear
1Armstrong Laboratory, Wright-Patterson Air Force Base, Ohio 45433-7400, USA. JLipscomb@AL.WPAFB.AF.MIL
Abstract:
Chloral hydrate (CH), [302-17-0], is a human sedative useful in premature infants. No current epidemiological study supports increased cancer risk. CH is also a rodent toxicant and a P450-derived metabolite of trichloroethylene (TRI). P450 induction increases TRI toxicity in rodents. CH is very rapidly metabolized to trichloroacetic acid (TCA) and trichloroethanol (TCOH). Because TCA mediates some responses following TRI exposure, we assessed the metabolism of CH to TCA and TCOH by liver and blood of the rat, mouse, and human. Both TCA and TCOH are formed in blood and liver. The constants for hepatic TCA and TCOH formation are presented. The K(m) for hepatic TCOH formation is at least ten-fold lower than for TCA formation in these species. Clearance values for TCOH are higher than for TCA. These data support TCOH as the first major metabolite of TRI and CH in vivo.
Related Concept Videos
Overview of Metabolism
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

